A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

Published:2014-09 Issue:9 Volume:38 Page:1025-1029
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Maddocks Kami,Ruppert Amy S.,Browning Rebekah,Jones Jeffrey,Flynn Joseph,Kefauver Cheryl,Gao Yue,Jiang Yao,Rozewski Darlene M.,Poi Ming,Phelps Mitch A.,Harper Erica,Johnson Amy J.,Byrd John C.,Andritsos Leslie A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion;List;N Engl J Med,2006

2. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients;Pellagatti;Proc Natl Acad Sci USA,2007

3. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma;Richardson;Blood,2006

4. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma;Rajkumar;Blood,2005

5. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle-cell lymphoma;Habermann;Brit J Haem,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice;Cancer Chemotherapy and Pharmacology;2019-09-06

2. Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies;British Journal of Clinical Pharmacology;2019-02-27

3. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review;Leukemia & Lymphoma;2018-03-21

4. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia;Expert Opinion on Pharmacotherapy;2017-05-16

5. Lenalidomide in the treatment of chronic lymphocytic leukemia;Expert Opinion on Investigational Drugs;2017-04-17